Chemomab Therapeutics Ltd.

Develops antibody drugs neutralizing CCL24 for severe fibro-inflammatory diseases.

CMMB | US

Overview

Corporate Details

ISIN(s):: US16385C1045 (+1 more)
LEI:
Country:: United States of America
Address:: KIRYAT ATIDIM, BUILDING 7, 6158002 TEL AVIV
Website:: https://www.chemomab.com/
Sector:: Manufacturing
Industry:: Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Chemomab Therapeutics Ltd. is a clinical-stage biotechnology company developing innovative therapeutics for fibro-inflammatory diseases with high unmet medical needs. The company's approach is centered on its discovery of the soluble protein CCL24 as a key driver of the vicious cycle of fibrosis and inflammation. Its lead product candidate, nebokitug (CM-101), is a first-in-class, dual-activity monoclonal antibody designed to bind to and neutralize CCL24. Nebokitug has demonstrated disease-modifying potential and a favorable safety profile in multiple clinical trials for severe fibrotic diseases. Following positive Phase 2 data, Chemomab is preparing for a potential Phase 3 trial in primary sclerosing cholangitis (PSC), for which nebokitug has received FDA Fast Track and Orphan Drug designations.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.

Quick Filters:

Filters

Filing Type

Language

Start date

End date

Clear

Bulk Actions:

	Date	Filing	Language	Size	Actions
No filings match the current criteria.

Automate Your Workflow. Get a real-time feed of all Chemomab Therapeutics Ltd. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Chemomab Therapeutics Ltd.

This data is available as part of our premium data solutions. Contact our team for access.

Request This Data

Need More History? Access decades of standardized financials for Chemomab Therapeutics Ltd. via our API.

Get Historical Data →

Insider Transactions

Date	Insider Name	Position	Type	Shares	Value
No insider transactions recorded for this company.

Peer Companies

Company	Country	Ticker
IMPACT BIOMEDICAL INC. Develops biopharma, preservatives, and bioplastics for healthcare and pathogen protection.	United States of America	IBO
Imunon, Inc. Developing DNA-based immunotherapies for oncology and infectious diseases.	United States of America	IMNN
IN8BIO, INC. Clinical-stage biopharma developing gamma-delta T cell therapies for solid & hematological tumors.	United States of America	INAB
Incanthera plc Develops targeted dermatology & oncology therapies using unique formulation & delivery technologies.	United Kingdom	INC
INCYTE CORP Develops proprietary therapeutics for serious unmet needs in oncology and inflammation.	United States of America	INCY
Indaptus Therapeutics, Inc. Develops immunotherapies using engineered bacteria to treat cancer and viral infections.	United States of America	INDP
Indivior PLC Develops pharmaceuticals for opioid use disorder, addiction, and serious mental illnesses.	United Kingdom	INDV
INDIVIOR PLC A pharmaceutical firm developing medicines for addiction and serious mental illnesses.	United States of America	INDV
Infant Bacterial Therapeutics Develops live bacterial medicines to prevent rare, severe gut diseases in premature infants.	Sweden	IBT
InflaRx N.V. Develops complement system inhibitors for severe inflammatory diseases and immuno-dermatology.	United States of America	IFRX